Relationship between Helicobacter Pylori infection and Gastro-esophageal Reflux Disease
DOI:
https://doi.org/10.63682/jns.v14i32S.9980Keywords:
Gastro-esophageal reflux disease (GERD), H. pylori (Hp), Non Erosive Reflux Disease (NERD), Erosive Esophagitis (EE)Abstract
Background:According to research, eradication of Helicobacter Pylori (Hp) infection may be followed by development of Gastro-Esophageal Reflux Disease (GERD), there has been concern regarding the interactions between Hp and GERD.
Aim: This study aims to investigate the relationship between Helicobacter Pylori (H. pylori), and oesophagitis (non-erosive or erosive) in patients with reflux symptoms.
Material and method: A total of 50 patients, fulfilling the inclusion criteria, were enrolled after taking informed consent. Endoscopy (and/or non-invasive tests like stool antigen test SAT, Serology: Non-invasive) was performed in all patients. On endoscopy, focusing on severity of esophagitis, either non-erosive or erosive esophagitis. During endoscopy, tissue biopsies were obtained for histopathology, which were then forwarded to the pathology lab for H. pylori detection.
Results: Out of the total of 50 individuals, males were 21(42%) and females were 29(58%). The mean age of the study population was 36.01+7.41 (ranged 15-65) years. H. Pylori was reported in 15(30%) cases, signifying that 35(70%) of GERD cases were H. Pylori negative. Out of a total of 50 participants, the endoscopic findings revealed Non Erosive Reflux Disease (NERD) in 42(84%) cases and Erosive Esophagitis in 8(16%) cases. H. Pylori was positive in 3(20%) of erosive esophagitis patients and in 12(80 %) of NERD patients, (P< 0.3).
Conclusion: The present study concluded that H. Pylori was present in 30% cases of GERD. Out of which, non-erosive reflux disease was associated with a greater frequency of helicobacter infection. Overall, the patients having GERD are more probable to have non-erosive reflux disease versus erosive esophagitis on endoscopy.
Downloads
References
1. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease. Gut 1997; 41: 277–280
2. . Abadi ATB. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches. J Pathog. 2018 May 22;2018:9064952. Doi: 10.1155/2018/9064952.
3. . Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, et al. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024 Apr;166(4):605-619. Doi: 10.1053/j.gastro.2023.12.022.
4. . Gatopoulou A, Mimidis K, Giatromanolaki A, Polichronidis A, Lirantzopoulos N, Sivridis E, Minopoulos G. Impact of Helicobacter pylori infection on histological changes in non-erosive reflux disease. World J Gastroenterol 2004; 10(8): 1180-1182 [PMID: 15069722 DOI: 10.3748/wjg.v10.i8.1180]
5. . Ashktorab H, Entezari O, Nouraie M, Dowlati E, Frederick W, Woods A, Lee E, Brim H, Smoot DT, Ghadyari F, Kamangar F, Razjouyan. H. Helicobacter pylori protection against reflux esophagitis. Dig Dis Sci. 2012 Nov;57(11):2924-8. Doi: 10.1007/s10620-012-2349-3. Epub 2012 Sep 26. PMID: 23010740; PMCID: PMC3673721.
6. . Li A, Zhang Y, Chen K, Quan X, Yin K Cui M, et al. Association between infection of Helicobacter pylori and the risk of reflux oesophagitis occurrence or recurrence: a systematic review and meta-analysis. Original research, 26 June 2025. Volume 3, Issue 2. https://egastroenterology.bmj.com/
7. . Jonaitis L, Pellicano R, Kupcinskas L. Helicobacter pylori and nonmalignant upper gastrointestinal diseases. Helicobacter. 2018 Sep;23 Suppl 1:e12522. Doi: 10.1111/hel.12522. PMID: 30203583.
8. . Pace F, Porro GB. Gastroesophageal reflux and Helicobacter pylori: a review. World J Gastroenterol. 2000 Jun 15;6(3):311–314. Doi: 10.3748/wjg.v6.i3.311
9. . Scida S, Russo M, Miraglia C, Leandro G, Franzoni L, Meschi T, et al. Relationship between Helicobacter pylori infection and GERD. Acta Biomed. 2018;89(Suppl 8):40–43. Doi: 10.23750/abm.v89i8-S.7918
10. . Schubert ML, et al. Gastric Peptides-Gastrin and Somatostatin. Compr Physiol. 2020. 10:197-228. )))))
11. Zhao T, Liu F, Li Y. Effects of Helicobacter pylori eradication on esophageal motility, esophageal acid exposure, and gastroesophageal reflux disease symptoms. Front. Cell. Infect. Microbiol., 08 March 2023. Volume 13 – 2023 | https://doi.org/10.3389/fcimb.2023.1082620
12. . Wang H, Qu Y, Lin Y, Liu Z, Lagergren J, Yuan S, et al. Helicobacter pylori Infection (and Eradication) in Relation to Gastroesophageal Reflux Disease. Journal of Gastroenterology and Hepatology Volume 40, Issue 10 pp. 2391-2401. July 2025. https://doi.org/10.1111/jgh.70009
13. . Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017;10:243–251. Doi: 10.1177/1756283X16681701. [DOI] [PMC free article] [PubMed] [Google Scholar]
14. . Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131–137. Doi: 10.1097/01.mcg.0000225631.07039.6d. [DOI] [PubMed] [Google Scholar]
15. . Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430–440. Doi: 10.1136/gutjnl-2016-313589. [DOI] [PubMed] [Google Scholar].
16. . Bezmin Abadi AT. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches. J Pathog. 2018 May 22;2018:9064952. Doi: 10.1155/2018/9064952.
17. . Zhao T, Liu F, Li Y. Effects of Helicobacter pylori eradication on esophageal motility, esophageal acid exposure, and gastroesophageal reflux disease symptoms. Front. Cell. Infect. Microbiol., 08 March 2023. Sec. Clinical and Diagnostic Microbiology and Immunology. Volume 13 – 2023 | https://doi.org/10.3389/fcimb.2023.1082620
18. . Niknam R, Lankarani KB, Moghadami M, Taghavi SA, Zahiri L, Fallahi MJ. The association between helicobacter pylori infection and erosive gastroesophageal reflux disease; a cross-sectional study. BMC Infect Dis. 2022 Mar 19;22:267. Doi: 10.1186/s12879-022-07278-6
19. . Habib M, Younus I, Waseem MM, Qadir A, Iqbal S, Rasheed F. The H. Pylori Infection, Erosive Esophagitis & NonErosive Reflux Disease in GERD. J Pak Soc Intern Med. 2024;5(4): 716-719.
20. Gatopoulou A, Mimidis K, Giatromanolaki A, Polichronidis A, Lirantzopoulos N, Sivridis E, Minopoulos G. Impact of Helicobacter pylori infection on histological changes in non-erosive reflux disease. World J Gastroenterol 2004; 10(8): 1180-1182 URL: https://www.wjgnet.com/1007-9327/full/v10/i8/1180.htm DOI: https://dx.doi.org/10.3748/wjg.v10.i8.1180
21. . Yılmaz S, Gisi K, Cetinkaya A, Kantarceken B, Ciralik H. Relationship between Helicobacter pylori infection and gastroesophageal reflux disease. Prz Gastroenterol. 2024 Dec 2;19(4):423–427. Doi: 10.5114/pg.2024.145379.
22. . Salman Al Gharbawi H, Mohammed AL-Hadithi T. The prevalence of Helicobacter pylori infection in Erosive and non-erosive gastro-esophageal reflux disease. Int. J. Adv. Res. Biol. Sci. (2019). 6(4): 101-106.
23. Ashktorab H, Entezari O, Nouraie M, Dowlati E, Frederick W, Woods A, Lee E, Brim H, Smoot DT, Ghadyari F, Kamangar F, Razjouyan. H. Helicobacter pylori protection against reflux esophagitis. Dig Dis Sci. 2012 Nov;57(11):2924-8. Doi: 10.1007/s10620-012-2349-3. Epub 2012 Sep 26. PMID: 23010740; PMCID: PMC3673721.
24. . Malfertheiner P, Nocon M, Vieth M. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care – the ProGERD study. Aliment Pharmacol Ther. 2012;35:154–164. Doi: 10.1111/j.1365-2036.2011.04901.x. [DOI] [PubMed] [Google Scholar]
25. Khademi H, Radmard AR, Malekzadeh F, et al. Diagnostic accuracy of age and alarm symptoms for upper GI malignancy in patients with dyspepsia in a GI clinic: a 7-year cross-sectional study. PLoS One. 2012;7:0. Doi: 10.1371/journal.pone.0039173. [DOI] [PMC free article] [PubMed] [Google Scholar]
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
